Proliferative human cell sources applied as biocomponent in bioartificial livers: A review

Expert Opinion on Biological Therapy

Volumn 12, Issue 7, 2012, Pages 905-921

  Nibourg, Geert A A ^a   Chamuleau, Robert A F M ^a   Van Gulik, Thomas M ^a   Hoekstra, Ruurdtje ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Bioartificial liver; Biocomponent; Cell source; Human

Indexed keywords

ACUTE LIVER FAILURE; BIOARTIFICIAL LIVER; CELL PROLIFERATION; DEVICES; DNA MODIFICATION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; LIVER DEVELOPMENT; LIVER FUNCTION; MEDLINE; MESENCHYMAL STEM CELL; NONHUMAN; PERFORMANCE; REVIEW; SYSTEMATIC REVIEW;

BIOCOMPATIBLE MATERIALS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HUMANS; LIVER, ARTIFICIAL; STEM CELLS;

EID: 84862179894     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.685714     Document Type: Review

References (105)

1. Bernal W, Auzinger G, Dhawan A, et al. Acute liver failure. Lancet 2010;376:190-201
2. Liou IW, Larson AM. Role of liver transplantation in acute liver failure. Semin Liver Dis 2008;28:201-9
3. Van de Kerkhove MP, Hoekstra R, Chamuleau RA, et al. Clinical application of bioartificial liver support systems. Ann Surg 2004;240:216-30
4. Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology 2001;34:447-55
5. Sgroi A, Serre-Beinier V, Morel P, et al. What clinical alternatives to whole liver transplantation?Current status of artificial devices and hepatocyte transplantation. Transplantation 2009;87:457-66
6. Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: Present and future. Gut 2009;58:1690-702
7. Butterworth RF. Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: Potential for improvement following their removal by liver assist devices. Liver Int 2003;23(Suppl 3):5-9
8. Moroni F, Carpenedo R, Venturini I, et al. Oxindole in pathogenesis of hepatic encephalopathy. Lancet 1998;351:1861
9. Bjerring PN, Hauerberg J, Jorgensen L, et al. Brain hypoxanthine concentration correlates to lactate/pyruvate ratio but not intracranial pressure in patients with acute liver failure. J Hepatol 2010;53:1054-8
10. Li Y, Dong JB, Wu MP. Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur J Pharmacol 2008;590:417-22
11. Vilstrup H, Iversen J, Tygstrup N. Glucoregulation in acute liver failure. Eur J Clin Invest 1986;16:193-7
12. Melchior GW, Castle CK, Murray RW, et al. Apolipoprotein A-I metabolism in cholesteryl ester transfer protein transgenic mice. Insights into the mechanisms responsible for low plasma high density lipoprotein levels. J Biol Chem 1994;269:8044-51
13. Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: The ups and downs. J Hepatol 2010;53:362-71
14. Wong F. Drug insight: The role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007;54:43-51
15. Wu Z, Han M, Chen T, et al. Acute liver failure: Mechanisms of immune-mediated liver injury. Liver Int 2010;30:782-94
16. Sauer IM, Zeilinger K, Obermayer N, et al. Primary human liver cells as source for modular extracorporeal liver support - a preliminary report. Int J Artif Organs 2002;25:1001-5
17. Baccarani U, Sanna A, Cariani A, et al. Isolation of human hepatocytes from livers rejected for liver transplantation on a national basis: Results of a 2-year experience. Liver Transpl 2003;9:506-12
18. Flendrig LM, Chamuleau RA, Maas MA, et al. Evaluation of a novel bioartificial liver in rats with complete liver ischemia: Treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability. J Hepatol 1999;30:311-20
19. Flendrig LM, Calise F, Di Florio E, et al. Significantly improved survival time in pigs with complete liver ischemia treated with a novel bioartificial liver. Int J Artif Organs 1999;22:701-9
20. Tsiaoussis J, Newsome PN, Nelson LJ, et al. Which hepatocyte will it be?Hepatocyte choice for bioartificial liver support systems. Liver Transpl 2001;7:2-10.. Clear review with list of required functions for BAL biocomponents.
21. Chamuleau RA, Deurholt T, Hoekstra R. Which are the right cells to be used in a bioartificial liver?Metab Brain Dis 2005;20:327-35
22. Aden DP, Fogel A, Plotkin S, et al. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979;282:615-16
23. Nyberg SL, Remmel RP, Mann HJ, et al. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg 1994;220:59-67. The first report on a BAL with the HepG2 liver cell line.
24. Yamashita Y, Shimada M, Tsujita E, et al. Polyurethane foam/spheroid culture system using human hepatoblastoma cell line (Hep G2) as a possible new hybrid artificial liver. Cell Transplant 2001;10:717-22
25. Hongo T, Kajikawa M, Ishida S, et al. Three-dimensional high-density culture of HepG2 cells in a 5-ml radial-flow bioreactor for construction of artificial liver. J Biosci Bioeng 2005;99:237-44
26. Nibourg GA, Huisman MT, van der Hoeven TV, et al. Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application. Liver Transpl 2010;16:1075-85
27. Coward SM, Legallais C, David B, et al. Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma. Artif Organs 2009;33:1117-26
28. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009;324:1029-33
29. Fukuda J, Okamura K, Nakazawa K, et al. Efficacy of a polyurethane foam/spheroid artificial liver by using human hepatoblastoma cell line (Hep G2). Cell Transplant 2003;12:51-8
30. Rahman TM, Selden C, Khalil M, et al. Alginate-encapsulated human hepatoblastoma cells in an extracorporeal perfusion system improve some systemic parameters of liver failure in a xenogeneic model. Artif Organs 2004;28:476-82
31. Kelly JH, Koussayer T, He D, et al. Assessment of an extracorporeal liver assist device in anhepatic dogs. Artif Organs 1992;16:418-22
32. Carraro A, Hsu WM, Kulig KM, et al. In vitro analysis of a hepatic device with intrinsic microvascular-based channels. Biomed Microdevices 2008;10:795-805
33. David B, Dufresne M, Nagel MD, et al. In vitro assessment of encapsulated C3A hepatocytes functions in a fluidized bed bioreactor. Biotechnol Prog 2004;20:1204-12
34. Hoekstra R, Deurholt T, ten Bloemendaal L, et al. Assessment of in vitro applicability of reversibly immortalized NKNT-3 cells and clonal derivatives. Cell Transplant 2006;15:423-33
35. Chen G, Palmer AF. Hemoglobin regulates the metabolic, synthetic, detoxification, and biotransformation functions of hepatoma cells cultured in a hollow fiber bioreactor. Tissue Eng Part A 2010;16:3231-40
36. Gautier A, Carpentier B, Dufresne M, et al. Impact of alginate type and bead diameter on mass transfers and the metabolic activities of encapsulated C3A cells in bioartificial liver applications. Eur Cell Mater 2011;21:94-106
37. Mavri-Damelin D, Damelin LH, Eaton S, et al. Cells for bioartificial liver devices: The human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 2007;99:644-651
38. Kinasiewicz A, Smietanka A, Gajkowska B, et al. Impact of oxygenation of bioartificial liver using perfluorocarbon emulsion perftoran on metabolism of human hepatoma C3A cells. Artif Cells Blood Substit Immobil Biotechnol 2008;36:525-34
39. Kinasiewicz A, Gautier A, Lewinska D, et al. Culture of C3A cells in alginate beads for fluidized bed bioartificial liver. Transplant Proc 2007;39:2911-13
40. Kinasiewicz A, Gautier A, Lewiska D, et al. Three-dimensional growth of human hepatoma C3A cells within alginate beads for fluidized bioartificial liver. Int J Artif Organs 2008;31:340-7
41. Kinasiewicz A, Smietanka A, Dudzinski K, et al. Spongy polyethersulfone membrane for hepatocyte cultivation: Studies on human hepatoma C3A cells. Artif Organs 2008;32:747-52
42. Kelly JH, Koussayer T, He DE, et al. An improved model of acetaminophen-induced fulminant hepatic failure in dogs. Hepatology 1992;15:329-35
43. Sussman NL, Chong MG, Koussayer T, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992;16:60-5
44. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-51
45. Millis JM, Cronin DC, Johnson R, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: System modifications and clinical impact. Transplantation 2002;74:1735-46
46. Kosuge M, Takizawa H, Maehashi H, et al. A comprehensive gene expression analysis of human hepatocellular carcinoma cell lines as components of a bioartificial liver using a radial flow bioreactor. Liver Int 2007;27:101-8
47. Kanai H, Marushima H, Kimura N, et al. Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopathy. Artif Organs 2007;31:148-51
48. Kawada M, Nagamori S, Aizaki H, et al. Massive culture of human liver cancer cells in a newly developed radial flow bioreactor system: Ultrafine structure of functionally enhanced hepatocarcinoma cell lines. In Vitro Cell Dev Biol Anim 1998;34:109-15
49. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002;99:15655-60.. This is the first report of the HepaRG cell line, which displays unparalleled high and broad hepatic functionality for a human hepatoma cell line.
50. Guillouzo A, Corlu A, Aninat C, et al. The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 2006;168:66-73
51. Darnell M, Schreiter T, Zeilinger K, et al. Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab Dispos 2011;39:1131-8
52. Flendrig LM, la Soe JW, Jorning GG, et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol 1997;26:1379-92
53. Murray AW. Recycling the cell cycle: Cyclins revisited. Cell 2004;116:221-34
54. Shay JW, Wright WE. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis 2005;14:867-74
55. Werner A, Duvar S, Muthing J, et al. Cultivation and characterization of a new immortalized human hepatocyte cell line, HepZ, for use in an artificial liver support system. Ann NY Acad Sci 1999;875:364-8
56. Werner A, Duvar S, Muthing J, et al. Cultivation of immortalized human hepatocytes HepZ on macroporous CultiSpher G microcarriers. Biotechnol Bioeng 2000;68:59-70
57. Deurholt T, van Til NP, Chhatta AA, et al. Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes. BMC Biotechnol 2009;9:89
58. Poyck PP, van Wijk AC, van der Hoeven TV, et al. Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J Hepatol 2008;48:266-75
59. Akiyama I, Tomiyama K, Sakaguchi M, et al. Expression of CYP3A4 by an immortalized human hepatocyte line in a three-dimensional culture using a radial-flow bioreactor. Int J Mol Med 2004;14:663-8
60. Fukaya K, Asahi S, Nagamori S, et al. Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT. In Vitro Cell Dev Biol Anim 2001;37:266-9
61. Kobayashi N, Okitsu T, Nakaji S, et al. Hybrid bioartificial liver: Establishing a reversibly immortalized human hepatocyte line and developing a bioartificial liver for practical use. J Artif Organs 2003;6:236-44
62. Kobayashi N. Life support of artificial liver: Development of a bioartificial liver to treat liver failure. J Hepatobiliary Pancreat Surg 2009;16:113-17
63. Deurholt T, ten Bloemendaal L, Chhatta AA, et al. In vitro functionality of human fetal liver cells and clonal derivatives under proliferative conditions. Cell Transplant 2006;15:811-22
64. Poyck PP, Hoekstra R, van Wijk AC, et al. Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver. Liver Transpl 2007;13:589-98
65. Ring A, Gerlach J, Peters G, et al. Hepatic maturation of human fetal hepatocytes in four-compartment three-dimensional perfusion culture. Tissue Eng Part C Methods 2010;16:835-45
66. Schmelzer E, Triolo F, Turner ME, et al. Three-dimensional perfusion bioreactor culture supports differentiation of human fetal liver cells. Tissue Eng Part A 2010;16:2007-16
67. Mitaka T, Kojima T, Mizuguchi T, et al. Growth and maturation of small hepatocytes isolated from adult rat liver. Biochem Biophys Res Commun 1995;214:310-17
68. Pavlic M, Libiseller K, Hermann M, et al. Small human hepatocytes in rotary culture for treatment of alcohol addicts?A pilot study. Alcohol Clin Exp Res 2007;31:729-36. This publication reports on the in vitro functionality of small human hepatocytes cultured in a rotary cell culture, displaying detoxification, as well as substantial ureagenesis and albumin production.
69. Wurm M, Lubei V, Caronna M, et al. Introduction of a novel prototype bioartificial liver support system utilizing small human hepatocytes in rotary culture. Tissue Eng Part A 2009;15:1063-73
70. Wurm M, Woess C, Libiseller K, et al. Challenging small human hepatocytes with opiates: Further characterization of a novel prototype bioartificial liver. Tissue Eng Part A 2010;16:807-13
71. Fonsato V, Herrera MB, Buttiglieri S, et al. Use of a rotary bioartificial liver in the differentiation of human liver stem cells. Tissue Eng Part C Methods 2009;16:123-32. This publication reports the differentiation of human liver stem cells cultured in a BAL. They display a high level of CYP activity, ureagenesis, and albumin production.
72. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22
73. Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2007;2:e941.. This publication reports the efficacy of a BAL based on human mesenchymal stem cells in a rat model of D-galactosamine-induced ALF.
74. Kazemnejad S, Allameh A, Soleimani M, et al. Biochemical and molecular characterization of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel three-dimensional biocompatible nanofibrous scaffold. J Gastroenterol Hepatol 2009;24:278-87
75. Miki T, Ring A, Gerlach J. Hepatic differentiation of human embryonic stem cells is promoted by three-dimensional dynamic perfusion culture conditions. Tissue Eng Part C Methods 2011;17:557-68
76. Enosawa S, Miyashita T, Suzuki S, et al. Long-term culture of glutamine synthetase-transfected HepG2 cells in circulatory flow bioreactor for development of a bioartificial liver. Cell Transplant 2000;9:711-15
77. Enosawa S, Miyashita T, Saito T, et al. The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model. Cell Transplant 2006;15:873-80
78. Enosawa S, Miyashita T, Fujita Y, et al. In vivo estimation of bioartificial liver with recombinant HepG2 cells using pigs with ischemic liver failure. Cell Transplant 2001;10:429-33
79. Enosawa S, Miyashita T, Tanaka H, et al. Prolongation of survival of pigs with ischemic liver failure by treatment with a bioartificial liver using glutamine synthetase transfected recombinant HepG2. Transplant Proc 2001;33:1945-7
80. Wang N, Tsuruoka S, Yamamoto H, et al. The bioreactor with CYPA4- and glutamine synthetase-introduced HepG2 cells: Treatment of hepatic failure dog with diazepam overdose. Artif Organs 2005;29:681-4. This publications reports on the efficacy of a BAL based on HepG2 cells overexpressing GS and CYP3A4 in a dog model of ALF induced by total liver ischemia and an overdose of diazepam.
81. Okitsu T, Kobayashi N, Jun HS, et al. Transplantation of reversibly immortalized insulin-secreting human hepatocytes controls diabetes in pancreatectomized pigs. Diabetes 2004;53:105-12
82. Shinoda M, Tilles AW, Kobayashi N, et al. A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats. J Surg Res 2007;137:130-40
83. Inoue Y, Miyazaki M, Tsuji T, et al. Reactivation of liver-specific gene expression in an immortalized human hepatocyte cell line by introduction of the human HNF4alpha2 gene. Int J Mol Med 2001;8:481-7
84. Bhatia SN, Balis UJ, Yarmush ML, et al. Effect of cell-cell interactions in preservation of cellular phenotype: Cocultivation of hepatocytes and nonparenchymal cells. FASEB J 1999;13:1883-900
85. Saito M, Matsuura T, Masaki T, et al. Reconstruction of liver organoid using a bioreactor. World J Gastroenterol 2006;12:1881-8
86. Endo M, Enosawa S, Ozaki M, et al. Artificial mimicking of physiological active transport by a membrane co-cultured with two different cells: Hepatic origin HepG2 and renal origin PCTL-MDR. Artif Organs 2002;26:806-11
87. Tsuruoka S, Sugimoto KI, Ueda K, et al. Removal of digoxin and doxorubicin by multidrug resistance protein-overexpressed cell culture in hollow fiber. Kidney Int 1999;56:154-63
88. Takahashi M, Sakurai M, Enosawa S, et al. Double-compartment cell culture apparatus: Construction and biochemical evaluation for bioartificial liver support. Cell Transplant 2006;15:945-52
89. Hoekstra R, Nibourg GAA, Van der Hoeven TV, et al. The HepaRG cell line is suitable for bioartificial liver application. Int J Biochem Cell Biol 2011;43:1483-9
90. Yagi H, Parekkadan B, Suganuma K, et al. Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure. Tissue Eng Part A 2009;15:3377-88
91. Carraro A, Flaibani M, Cillo U, et al. A combining method to enhance the in vitro differentiation of hepatic precursor cells. Tissue Eng Part C Methods 2011;16:1543-51
92. Brieva TA, Moghe PV. Functional engineering of hepatocytes via heterocellular presentation of a homoadhesive molecule, E-cadherin. Biotechnol Bioeng 2001;76:295-302
93. Hussain SZ, Sneddon T, Tan X, et al. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res 2004;292:157-69
94. Snykers S, De Kock J, Rogiers V, et al. In vitro differentiation of embryonic and adult stem cells into hepatocytes: State of the art. Stem Cells 2009;27:577-605
95. Mancone C, Conti B, Amicone L, et al. Proteomic analysis reveals a major role for contact inhibition in the terminal differentiation of hepatocytes. J Hepatol 2010;52:234-43
96. Kobayashi N, Fujiwara T, Westerman KA, et al. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science 2000;287:1258-62
97. Ryall J, Rachubinski RA, Nguyen M, et al. Regulation and expression of carbamyl phosphate synthetase I mRNA in developing rat liver and Morris hepatoma 5123D. J Biol Chem 1984;259:9172-6
98. Kobayashi N, Noguchi H, Totsugawa T, et al. Insertion of a suicide gene into an immortalized human hepatocyte cell line. Cell Transplant 2001;10:373-6
99. Shimada M, Yamashita Y, Tanaka S, et al. Characteristic gene expression induced by polyurethane foam/spheroid culture of hepatoma cell line, Hep G2 as a promising cell source for bioartificial liver. Hepatogastroenterology 2007;54:814-820
100. Sussman NL, Gislason GT, Conlin CA, et al. The Hepatix extracorporeal liver assist device: Initial clinical experience. Artif Organs 1994;18:390-396
101. Harm S, Stroble K, Hartmann J, et al. Alginate-encapsulated human hepatoma C3A cells for use in a bioartificial liver device - the hybrid-MDS. Int J Artif Organs 2009;32:769-778
102. Iwahori T, Matsuno N, Johjima Y, et al. Radial flow bioreactor for the creation of bioartificial liver and kidney. Transplant Proc 2005;37:212-214
103. Iwahori T, Matsuura T, Maehashi H, et al. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 2003;37:665-673
104. Sun BS, Pan J, Clayton MM, et al. Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis. J Cell Physiol. 2004;201:447-58
105. Lu DD, Chen YC, Zhang XR, et al. The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma. Yale J Biol Med. 2003;76:55-62